JP2017529852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529852A5 JP2017529852A5 JP2017516368A JP2017516368A JP2017529852A5 JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5 JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- respond
- egfr
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 17
- 229940121647 egfr inhibitor Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 claims 5
- 108091070501 miRNA Proteins 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 239000013610 patient sample Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306490.5A EP3000895A1 (en) | 2014-09-26 | 2014-09-26 | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| EP14306490.5 | 2014-09-26 | ||
| PCT/EP2015/072095 WO2016046365A1 (en) | 2014-09-26 | 2015-09-25 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529852A JP2017529852A (ja) | 2017-10-12 |
| JP2017529852A5 true JP2017529852A5 (https=) | 2018-10-25 |
Family
ID=51663116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516368A Withdrawn JP2017529852A (ja) | 2014-09-26 | 2015-09-25 | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170298442A1 (https=) |
| EP (2) | EP3000895A1 (https=) |
| JP (1) | JP2017529852A (https=) |
| KR (1) | KR20170086469A (https=) |
| CN (1) | CN107075583A (https=) |
| AU (1) | AU2015323744A1 (https=) |
| BR (1) | BR112017005421A2 (https=) |
| CA (1) | CA2961434A1 (https=) |
| MX (1) | MX2017003832A (https=) |
| WO (1) | WO2016046365A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2749651T3 (es) | 2015-02-11 | 2020-03-23 | Region Midtjylland | Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina |
| ES2724404T3 (es) * | 2015-02-27 | 2019-09-10 | Qiagen Gmbh | Un procedimiento basado en microARN para evaluar el pronóstico de un paciente de cáncer de próstata |
| CN108034727B (zh) * | 2018-01-18 | 2021-05-28 | 四川大学华西医院 | 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途 |
| KR102480430B1 (ko) * | 2020-10-21 | 2022-12-21 | 순천향대학교 산학협력단 | 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도 |
| CN119303090B (zh) * | 2024-10-15 | 2025-06-20 | 中国医学科学院北京协和医院 | miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523216C (zh) | 2001-03-02 | 2009-08-05 | 匹兹堡大学 | Pcr方法 |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| EP2419522A4 (en) | 2009-04-17 | 2012-10-31 | Glen Weiss | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
| ES2661238T3 (es) * | 2009-06-19 | 2018-03-28 | Merck Patent Gmbh | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| JP6342329B2 (ja) | 2011-11-25 | 2018-06-13 | アンテグラジャンＩｎｔｅｇｒａｇｅｎ | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
| CN104046679B (zh) * | 2013-03-11 | 2016-08-24 | 戴勇 | 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用 |
-
2014
- 2014-09-26 EP EP14306490.5A patent/EP3000895A1/en not_active Withdrawn
-
2015
- 2015-09-25 CN CN201580051832.9A patent/CN107075583A/zh active Pending
- 2015-09-25 AU AU2015323744A patent/AU2015323744A1/en not_active Abandoned
- 2015-09-25 US US15/513,223 patent/US20170298442A1/en not_active Abandoned
- 2015-09-25 CA CA2961434A patent/CA2961434A1/en not_active Abandoned
- 2015-09-25 WO PCT/EP2015/072095 patent/WO2016046365A1/en not_active Ceased
- 2015-09-25 BR BR112017005421A patent/BR112017005421A2/pt not_active IP Right Cessation
- 2015-09-25 MX MX2017003832A patent/MX2017003832A/es unknown
- 2015-09-25 JP JP2017516368A patent/JP2017529852A/ja not_active Withdrawn
- 2015-09-25 KR KR1020177009944A patent/KR20170086469A/ko not_active Withdrawn
- 2015-09-25 EP EP15767530.7A patent/EP3198028B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533960A5 (https=) | ||
| Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
| Lohaus et al. | HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) | |
| Lechner et al. | Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma | |
| JP2017529852A5 (https=) | ||
| JP2017516458A5 (https=) | ||
| EP4435112A3 (en) | Compositions and methods for screening solid tumors | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| RU2014110228A (ru) | Диагностические маркеры | |
| EA201500327A1 (ru) | Неинвазивное определение метилома плода или опухоли по плазме | |
| MX2016004557A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| NZ627864A (en) | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Tini et al. | The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma | |
| Karagiannis et al. | IGF-IEc expression is associated with advanced differentiated thyroid cancer | |
| Loeschke et al. | Prognostic value of HMGA2, P16, and HPV in oral squamous cell carcinomas | |
| KR102241063B1 (ko) | 예측성 바이오마커에 대한 검정법 | |
| KR20170086469A (ko) | Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 | |
| Schweiger et al. | Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling | |
| Linardou et al. | Prognostic significance of VEGFC and VEGFR1 mRNA expression according to HER2 status in breast cancer: a study of primary tumors from patients with high-risk early breast cancer participating in a randomized Hellenic Cooperative Oncology Group Trial | |
| Bai et al. | Association between downexpression of miR-1301 and poor prognosis in patients with glioma | |
| Farr et al. | Modern risk assessment for individualizing treatment concepts in early-stage breast cancer | |
| An et al. | Association of E2F3 expression with clinicopathological features of Wilms’ tumors | |
| RU2011142986A (ru) | Способы лечения и диагностики рака |